Can You Get COVID-19 Again? Replay our May 22 HDLive!

Follow Our Live Coverage of COVID-19 Developments

Antidepressant Targets Two Brain Chemicals

New users should be monitored closely, FDA says

Please note: This article was published more than one year ago. The facts and conclusions presented may have since changed and may no longer be accurate. And "More information" links may no longer work. Questions about personal health should always be referred to a physician or other health care professional.

FRIDAY, Aug. 06, 2004 (HealthDayNews) -- The U.S. Food and Drug Administration has approved Eli Lilly's Cymbalta (duloxetine), a new adult antidepressant.

Cymbalta belongs to a newer class of antidepressants that targets norepinephrine and serotonin, two brain chemicals associated with depression.

It's the first antidepressant to be approved for sale in the United States since the FDA started to investigate whether antidepressants may increase the risk of suicide, according to the Associated Press.

Cymbalta initially wasn't part of the investigation, but it gained attention in February when a college student taking part in clinical studies of the drug hanged herself at the research facility. Lilly has insisted there's no evidence that the drug was to blame.

The FDA approved Cymbalta for treatment of major depression for up to nine weeks. As with similar medications, the drug will carry a label warning doctors and caregivers that patients should be closely monitored when they start taking Cymbalta or change doses.

Cymbalta should be on pharmacy shelves later this month. Visit the drug's Web site to learn more.

Last Updated: